HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, E. L. Articles by Shen, Y. Search for Related Content PubMed PubMed Citation Articles by Jones, E. L. Articles by Shen, Y.

The Annals of Thoracic Surgery, Vol 58, 378-384, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Interaction of age and coronary disease after valve replacement: implications for valve selection

EL Jones, WS Weintraub, JM Craver, RA Guyton and Y Shen
Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia.

The interaction of patient age and the presence of coronary artery disease (CAD) and its influence on survival were examined in 3,644 patients undergoing either aortic (AVR) or mitral (MVR) valve replacement with or without coronary artery bypass grafting (CABG) between 1974 and 1991. Emergency procedures were performed much more frequently in those undergoing MVR and CABG than in those undergoing AVR and CABG (18.8% and 6.7%, respectively). The adverse effect of CAD on median survival for patients of all ages undergoing either AVR or MVR was statistically significant (AVR without CAD 11.8 versus 8.7 years with CAD; MVR without CAD 12.7 versus 7.3 years with CAD; p < 0.0001). Survival in patients younger than 70 years without CABG who underwent either AVR or MVR was quite good (< 60 years: AVR, > 14 years; MVR, 15.4 years; 60 to 69 years: AVR, 10.4 years; MVR, 11.4 years). The most profound effect of CAD on patient survival after valve replacement was observed in patients 60 to 69 years of age who underwent MVR, in whom the median survival without CABG was 11.4 years versus 5.5 years with CABG (p < 0.0001). An emergency operative status was associated with a reduced early and late survival for those patients undergoing MVR, particularly those with CAD. By relating the Cox proportional hazard models for valve survival to patient survival, we found that, in those patients 70 years and older with and without CAD who underwent either AVR or MVR, the median patient survival was reduced sufficiently (5.5 versus 8.1 years) to justify use of a bioprosthetic valve.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				T. Gudbjartsson, T. Absi, and S. Aranki Mitral Valve Replacement Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068. [Full Text]

				M. LeBoutillier III and V. J. DiSesa Valvular and Ischemic Heart Disease Card. Surg. Adult, January 1, 2008; 3(2008): 1175 - 1192. [Full Text]

				L. H. Cohn Use of Heart Valves in Older Patients Circulation, May 3, 2005; 111(17): 2152 - 2153. [Full Text] [PDF]

				F. W. Mohr, S. Lehmann, V. Falk, S. Metz, C. Walther, N. Doll, A. Rastan, J. Gummert, and T. Walther Clinical Experience With Stentless Mitral Valve Replacement Ann. Thorac. Surg., March 1, 2005; 79(3): 772 - 775. [Abstract] [Full Text] [PDF]

				T. Walther, S. Lehmann, V. Falk, S. Metz, N. Doll, A. Rastan, M. Viehweg, M. Richter, J. Gummert, and F. W. Mohr Prospectively Randomized Evaluation of Stented Xenograft Hemodynamic Function in the Aortic Position Circulation, September 14, 2004; 110(11_suppl_1): II-74 - II-78. [Abstract] [Full Text] [PDF]

				R. S. Farivar and L. H. Cohn Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 969 - 975. [Abstract] [Full Text] [PDF]

				T. Walther, S. Lehmann, V. Falk, C. Walther, N. Doll, A. Rastan, S. Metz, J. Schneider, J. Gummert, and F. W. Mohr Midterm Results After Stentless Mitral Valve Replacement Circulation, September 9, 2003; 108(90101): II-85 - 89. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986. [Full Text]

				M. LeBoutillier III and V. J. DiSesa Valvular and Ischemic Heart Disease Card. Surg. Adult, January 1, 2003; 2(2003): 1057 - 1074. [Full Text]

				C. W. Akins, A. D. Hilgenberg, G. J. Vlahakes, T. E. MacGillivray, D. F. Torchiana, and J. C. Madsen Results of bioprosthetic versus mechanical aortic valve replacement performed with concomitant coronary artery bypass grafting Ann. Thorac. Surg., October 1, 2002; 74(4): 1098 - 1106. [Abstract] [Full Text] [PDF]

				T. E. David, J. Ivanov, S. Armstrong, C. M. Feindel, and G. Cohen Late results of heart valve replacement with the Hancock II bioprosthesis J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0268 - 278. [Abstract] [Full Text] [PDF]

				V. H. Thourani, W. S. Weintraub, J. M. Craver, E. L. Jones, J. P. Gott, W. M. Brown III, J. D. Puskas, and R. A. Guyton Influence of concomitant CABG and urgent/emergent status on mitral valve replacement surgery Ann. Thorac. Surg., September 1, 2000; 70(3): 778 - 783. [Abstract] [Full Text] [PDF]

				B. Iung VALVE DISEASE: Interface between valve disease and ischaemic heart disease Heart, September 1, 2000; 84(3): 347 - 352. [Full Text] [PDF]

				G. Cohen, T. E. David, J. Ivanov, S. Armstrong, and C. M. Feindel THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT J. Thorac. Cardiovasc. Surg., February 1, 1999; 117(2): 273 - 284. [Abstract] [Full Text] [PDF]

				C. W. Akins, M. J. Buckley, W. M. Daggett, A. D. Hilgenberg, G. J. Vlahakes, D. F. Torchiana, and J. C. Madsen Risk of Reoperative Valve Replacement for Failed Mitral and Aortic Bioprostheses Ann. Thorac. Surg., June 1, 1998; 65(6): 1545 - 1551. [Abstract] [Full Text] [PDF]

				C. W. Akins, W. M. Daggett, G. J. Vlahakes, A. D. Hilgenberg, D. F. Torchiana, J. C. Madsen, and M. J. Buckley Cardiac Operations in Patients 80 Years Old and Older Ann. Thorac. Surg., September 1, 1997; 64(3): 606 - 614. [Abstract] [Full Text]

				A. Abolhoda, S. Yu, J. R. Oyarzun, K. R. Allen, J. R. McCormick, S. Han, F. W. Kemp, J. D. Bogden, Q. Lu, and S. Gabbay No-React Detoxification Process: A Superior Anticalcification Method for Bioprostheses Ann. Thorac. Surg., December 1, 1996; 62(6): 1724 - 1730. [Abstract] [Full Text]

				J. I. Fann, D. C. Miller, KathleenA. Moore, R. S. Mitchell, P. E. Oyer, E. B. Stinson, R. C. Robbins, B. A. Reitz, and N. E. Shumway Twenty-Year Clinical Experience With Porcine Bioprostheses Ann. Thorac. Surg., November 1, 1996; 62(5): 1301 - 1311. [Abstract] [Full Text]

				X. Y. Jin, Z.-M. Zhang, D. G. Gibson, M. H. Yacoub, and J. R. Pepper Effects of Valve Substitute on Changes in Left Ventricular Function and Hypertrophy After Aortic Valve Replacement Ann. Thorac. Surg., September 1, 1996; 62(3): 683 - 690. [Abstract] [Full Text]

				C. W. Akins Long-Term Results With the Medtronic-Hall Valvular Prosthesis Ann. Thorac. Surg., March 1, 1996; 61(3): 806 - 813. [Abstract] [Full Text]

				D. M. Cosgrove, B. W. Lytle, P. C. Taylor, M. T. Camacho, R. W. Stewart, P. M. McCarthy, D. P. Miller, M. R. Piedmonte, and F. D. Loop The Carpentier-Edwards pericardial aortic valve: Ten-year results J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 651 - 662. [Abstract] [Full Text]

				A. C. Fiore, M. T. Swartz, T. G. Sharp, K. A. Kesler, H. B. Barner, K. S. Naunheim, G. L. Grunkemeier, D. A. Moroney, and G. C. Kaiser Double-Valve Replacement With Medtronic-Hall or St. Jude Valve Ann. Thorac. Surg., May 1, 1995; 59(5): 1113 - 1119. [Abstract] [Full Text]